ABIONYX Pharma Provides an Update on Its Business and Cash Position for the First Quarter of 2022
19 Mai 2022 - 6:25PM
Business Wire
- Focus of the Services activityon the Biotech's preclinical
studies in ophthalmology
- Determination of the strategic axes of clinical development
in ophthalmology
- Cash position of €5.9 million as of March 31, 2022
Regulatory News:
ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible),
a new generation biotech company dedicated to the discovery and
development of innovative therapies for patients, today provides an
update on its business and cash and cash equivalents as of March
31, 2022.
ABIONYX Pharma recorded a consolidated quarterly revenue of €1.2
million after removal of intra-group transactions. IRIS Pharma
recorded a quarterly revenue of €1.6 million. Regarding the
activity dedicated to the discovery and development of innovative
therapies aimed at improving the lives of patients, the Company did
not generate any revenue during this quarter. The consolidated
revenue reflects that, since the integration of IRIS Pharma, the
Biotech has decided to focus the efforts of the Services activity
on the preclinical studies of the bio-HDL in ophthalmology, in
order to determine the strategic axes of development to enter the
clinical phase as soon as possible. The Company will soon
communicate its strategy in ophthalmology.
In the renal franchise, the Phase 2a clinical trial for CER-001,
known as RACERS, is continuing in sepsis at high risk of developing
acute kidney injury, in partnership with the University of Bari. In
April, ABIONYX Pharma announced positive interim results from this
clinical trial demonstrating rapid reversal of the cytokine storm
in septic patients and rapid improvement in biomarkers of
inflammation, including leukocytosis, compared to standard therapy.
Final results of the study are expected to be available in the fall
of 2022.
In addition, the Company continues to receive new Compassionate
Access Authorization (CAA) requests for the bio-HDL (CER-001) from
several hospitals around the world.
The Company recalls that beyond a cash position of nearly €6
million and the total financing of Phase 2a by CBVF, an Italian
consortium, no dilutive financial instruments have been put in
place.
Next financial press release:
Cash position and activity update for Q2 2022, August 18,
2022
About ABIONYX Pharma
ABIONYX Pharma is a new generation biotech company that aims to
contribute to health through innovative therapies in indications
where there is no effective or existing treatment, even the rarest
ones. Thanks to its partners in research, medicine,
biopharmaceuticals and shareholding, the company innovates on a
daily basis to propose drugs for the treatment of renal and
ophthalmological diseases, or new HDL vectors used for targeted
drug delivery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220519005842/en/
NewCap Investor relations Louis-Victor Delouvrier Nicolas
Fossiez abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media relations Arthur Rouillé abionyx@newcap.eu
+33 (0)1 44 71 94 98
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024